Oliver Luxxe Assets LLC boosted its position in Allergan PLC. (NYSE:AGN) by 2.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,550 shares of the company’s stock after buying an additional 247 shares during the period. Allergan PLC. makes up about 2.0% of Oliver Luxxe Assets LLC’s holdings, making the stock its 18th biggest position. Oliver Luxxe Assets LLC’s holdings in Allergan PLC. were worth $3,051,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. GWM Advisors LLC grew its position in Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY grew its position in Allergan PLC. by 0.7% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its position in Allergan PLC. by 0.5% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after buying an additional 9 shares during the last quarter. Trust Co grew its position in Allergan PLC. by 0.8% in the 1st quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the last quarter. Finally, Berkeley Capital Partners LLC boosted its position in shares of Allergan PLC. by 0.3% during the 2nd quarter. Berkeley Capital Partners LLC now owns 3,721 shares of the company’s stock worth $905,000 after purchasing an additional 10 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Allergan PLC. (NYSE:AGN) opened at 231.21 on Wednesday. The stock’s 50 day moving average is $235.09 and its 200-day moving average is $237.04. The firm has a market cap of $77.29 billion, a P/E ratio of 7.04 and a beta of 1.18. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $3.35 EPS. Analysts forecast that Allergan PLC. will post $16.25 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.
TRADEMARK VIOLATION WARNING: “Oliver Luxxe Assets LLC Has $3.05 Million Position in Allergan PLC. (AGN)” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2888063/oliver-luxxe-assets-llc-has-3-05-million-position-in-allergan-plc-agn.html.
Several equities research analysts have commented on the stock. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. UBS AG restated an “outperform” rating and set a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Wells Fargo & Company restated an “outperform” rating and set a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Cantor Fitzgerald restated a “hold” rating on shares of Allergan PLC. in a research report on Tuesday, August 22nd. Finally, Argus restated a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $274.69.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.